A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

BACKGROUND In March 2003, several hospitals in Quebec, Canada, noted a marked increase in the incidence of Clostridium difficile-associated diarrhea. METHODS In 2004 we conducted a prospective study at 12 Quebec hospitals to determine the incidence of nosocomial C. difficile-associated diarrhea and its complications and a case-control study to identify risk factors for the disease. Isolates of C. difficile were typed by pulsed-field gel electrophoresis and analyzed for binary toxin genes and partial deletions in the toxin A and B repressor gene tcdC. Antimicrobial susceptibility was evaluated in a subgroup of isolates. RESULTS A total of 1703 patients with 1719 episodes of nosocomial C. difficile-associated diarrhea were identified. The incidence was 22.5 per 1000 admissions. The 30-day attributable mortality rate was 6.9 percent. Case patients were more likely than matched controls to have received fluoroquinolones (odds ratio, 3.9; 95 percent confidence interval, 2.3 to 6.6) or cephalosporins (odds ratio, 3.8; 95 percent confidence interval, 2.2 to 6.6). A predominant strain, resistant to fluoroquinolones, was found in 129 of 157 isolates (82.2 percent), and the binary toxin genes and partial deletions in the tcdC gene were present in 132 isolates (84.1 percent). CONCLUSIONS A strain of C. difficile that was resistant to fluoroquinolones and had binary toxin and a partial deletion of the tcdC gene was responsible for this outbreak of C. difficile-associated diarrhea. Exposure to fluoroquinolones or cephalosporins was a risk factor.

[1]  M. Samore,et al.  Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. , 1999, The New England journal of medicine.

[2]  I. Poxton,et al.  The pathogenicity of Clostridium difficile. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  P Sharkey,et al.  The importance of severity of illness in assessing hospital mortality. , 1990, JAMA.

[4]  A. Morris,et al.  Clostridium difficile colitis: an increasingly aggressive iatrogenic disease? , 2002, Archives of surgery.

[5]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[6]  K. K. Lai,et al.  Clostridium difficile-Associated Diarrhea Epidemiology, Risk Factors, and Infection Control , 1997, Infection Control & Hospital Epidemiology.

[7]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[8]  K. Aktories,et al.  Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins , 2004, Microbiology and Molecular Biology Reviews.

[9]  E. Rubin,et al.  Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain , 1988, Infection and immunity.

[10]  K. Tullus,et al.  A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  B. Sheppard,et al.  Clostridium difficile colitis: an increasing hospital-acquired illness. , 1995, American journal of surgery.

[12]  J. Silva,et al.  Analysis of the pathogenicity locus in Clostridium difficile strains. , 2000, The Journal of infectious diseases.

[13]  D. Decré,et al.  Prevalence and Characterization of a Binary Toxin (Actin-Specific ADP-Ribosyltransferase) from Clostridium difficile , 2004, Journal of Clinical Microbiology.

[14]  Mark A. Miller,et al.  N-CDAD in Canada: results of the Canadian Nosocomial Infection Surveillance Program 1997 N-CDAD Prevalence Surveillance Project. , 2001, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[15]  C. Surawicz,et al.  Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. , 1990, The Journal of infectious diseases.

[16]  D. O'neill,et al.  Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. , 1999, Age and ageing.

[17]  Carlene A. Muto,et al.  A Large Outbreak of Clostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use , 2005, Infection Control & Hospital Epidemiology.

[18]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[19]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[20]  Henry D. Isenberg,et al.  Manual of Clinical Microbiology , 1991 .

[21]  P. Mastrantonio,et al.  Molecular Analysis of the Pathogenicity Locus and Polymorphism in the Putative Negative Regulator of Toxin Production (TcdC) among Clostridium difficile Clinical Isolates , 2002, Journal of Clinical Microbiology.

[22]  R. Gaynes,et al.  Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  G. Corthier,et al.  Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. , 1996, Archives of internal medicine.

[24]  M. Samore,et al.  Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. , 1996, The American journal of medicine.

[25]  C. Sirio,et al.  Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications , 2002, Annals of surgery.

[26]  T. Hundsberger,et al.  Definition of the single integration site of the pathogenicity locus in Clostridium difficile. , 1996, Gene.

[27]  Mark A. Miller,et al.  Morbidity, Mortality, and Healthcare Burden of Nosocomial Clostridium Difficile-Associated Diarrhea in Canadian Hospitals , 2002, Infection Control & Hospital Epidemiology.

[28]  D. Gerding,et al.  Clostridium difficile--associated diarrhea. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  M. Wilcox,et al.  Pulsed-Field Gel Electrophoresis Can Yield DNA Fingerprints of Degradation-Susceptible Clostridium difficile Strains , 2002, Journal of Clinical Microbiology.

[30]  A. Harris,et al.  difficile–associated Diarrhea , 2022 .

[31]  Jon Brazier,et al.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe , 2005, The Lancet.